Background: Target enrichment coupled with next generation sequencing provide high-throughput approaches for screening several genes of interest. These approaches facilitate screening a panel of genes for mutations associated with inherited breast cancer for research, diagnostic, and genetic counseling applications. Objective: To evaluate the performance of our custom 13 gene breast cancer panel, based on singleplex PCR, developed by WaferGen BioSystems. The panel was evaluated using patientderived DNA samples, in terms of target enrichment efficiency, off-target enrichment, uniformity of target capture, effect of GC content of target regions on coverage depth, and concordance with validated variant calls.
Introduction
Targeted sequencing of genomic regions of interest remains a viable way to study diseases with known genetic associations and could be routinely used in molecular diagnoses. It is cheaper, produces data that is more tractable, substantially faster to analyze, and more easily understood for functional interpretation compared to whole exome sequencing. Investigating a panel of multiple genes can inform clinicians and researchers of genetic variants that may be associated with breast cancer risk (Easton et al., 2015; Kurian et al., 2014; Walsh et al., 2010) . Breast cancer is the most prevalent cancer among women, and one of the leading causes of cancer deaths among women.
In 2013, 1.8 million women died from breast cancer worldwide (Global Burden of Disease Cancer Collaboration et al., 2015) . A number of genes of varying penetrance have been associated with susceptibility to breast cancer (Michailidou et al., 2013; Rahman et al., 2007; Wooster et al., 1995) .
Breast cancer gene panel testing is now commercially available for molecular biology applications, with a variety of pre-designed and customizable panels on offer. In this study we evaluated a custom panel designed for the SmartChip approach by WaferGen Biosystems Inc. (now acquired by Takara Bio USA Holdings, Inc.). Although the SmartChip has been evaluated using DNA derived from cancer cell lines (De Wilde et al., 2014) , to our knowledge an evaluation for its application in inherited breast cancer still needs to be presented. We designed our panel to capture the entire coding sequence of 13 genes frequently mutated in inherited breast cancer cases, representing a target of 150Kb in total. Our panel includes nine established breast cancer susceptibility genes with high and moderate risk. For these genes (BRCA1, BRCA2, ATM, CHEK2, TP53, CDH1, STK11, PALB2, PTEN) association with breast cancer risk has been established, primarily, on protein truncating variants (Easton et al., 2015) . Low risk or proposed breast cancer susceptibility genes BRIP1, RAD51C, RAD51D, and PPM1D were also included in spite of their relatively low mutation rate in inherited breast cancer cases (Slavin et al., 2017) . All but two (RAD51C, RAD51D) of the genes on our panel are captured in version 84 of the COSMIC cancer gene census list (Futreal et al., 2004) . A summarized description of target genes for our panel is presented in Table 1 .
Gene symbol

Name
Major associated cancer risk PCR-based target enrichment (TE) is commonly used to discover novel variants in known breast cancer susceptibility genes or validate mutations such as single nucleotide polymorphisms (SNPs) and small insertions and deletions (indels). Singleplex PCR strategies have been found to detect mutations present at less than 5% frequency in tumor samples (Kozarewa et al., 2015) . Mutations validated in this study include SNPs and indels. Additionally, primers are designed such that no known SNPs with population frequency greater than 0.5% are included in last 10 nucleotides on the 3' end of a primer, to minimize off-target hybridization and reduce risk of allelic dropouts (De Wilde et al., 2014) . Amplicons are designed to span beyond target exons and overlap each other to increase the probability of capturing target regions (Figure 1 ). Figure 1 . BRCA1 amplicons of Wafergen panel are mapped to BRCA1 exons of GRCh37/hg19 using UCSC genome browser (Kent et al., 2002) . Amplicons overlap target exons to maximize capture. Amplicons are designed to span exon-intron boundaries and untranslated regions. In this study, our goals were to assess how well our custom panel captures its target genes, examine the effect of GC content of target regions on coverage depth, and measure concordance in genotype calls between our panel and known variant calls obtained from Sanger sequencing and target enrichment using the Qiagen human breast cancer panel.
Summary of function
Materials and Methods
Samples
Peripheral blood samples from 36 hereditary breast cancer cases were selected for testing on our custom WaferGen breast cancer panel. A subset (19) of these samples were tested using the validation panel, Qiagen Human breast cancer panel. The Human Breast Cancer GeneRead DNAseq Gene Panel targets hotspots in 20 genes commonly mutated in human breast cancer samples using a multiplexed PCR assay. The Qiagen panel is compatible with both germline and tumor mutation profiling and shares a common target region with our custom panel. Genomic DNA (gDNA) was extracted from blood samples and quantified using Qubit dsDNA HS.
Target enrichment and library preparation
Purified genomic DNA from our Qiagen samples were subjected to target enrichment using the Nextera XT tagmentation protocol was used to prepare the sequencing library from WaferGen amplicons while the ligation-based NEBNext method for Illumina was used to prepare the sequencing library from Qiagen amplicons. WaferGen amplicons, due to their size (350 -749 bases), were fragmented prior to ligating read-specific sequencing primers, index, and adapter sequences. However, there was no fragmentation step in the library preparation for Qiagen samples because these amplicons are smaller (48 -143 bases).
Sequencing
Samples were sequenced by the McGill University and Génome Québec Innovation Centre sequencing service. All samples were sequenced on the Illumina HiSeq 2500 to produce 150bp, paired-end reads. Samples were sequenced in rapid run mode.
Data analysis
Raw sequencing data was filtered using Trimmomatic (Bolger et al., 2014) with Phred Quality score of 20 as cutoff. Filtered sequence reads for each sample were aligned to human reference genome build GRCh37/hg19 using BWA-MEM (Li and Durbin, 2010) . The alignment files were converted from SAM to BAM format and sorted. BEDtools (Quinlan and Hall, 2010) , and bamstats05 from the Jvarkit (Pierre, 2015) package were used to determine breadth and depth of coverage metrics for individual target intervals using each sample's BAM file. Coverage metrics for samples were aggregated for each panel using custom R scripts. Plots and statistics were also generated using R programming language for statistical computing (R Core Team, 2016) . Variant calling was done using HaplotypeCaller of GATK version 3.7-0-gcfedb67 (McKenna et al., 2010) , according to best practices. Variants for both sets of samples were called as a cohort. The resulting VCF file was annotated with dbSNP (Sherry et al., 2001) identifiers from dbSNP146 using SnpSift (Cingolani et al., 2012) . Variants were normalized using bcftools, and partial genotypes were converted to complete genotypes using genotype likelihood scores. Annotated VCF was filtered with the vcfR (Knaus and Grunwald, 2016) package and custom R scripts. Variants were filtered using total coverage threshold of 30. Only variants with dbSNP identifiers (rs IDs) were considered. For the Qiagen panel, only variants outside of the target enrichment primer regions were considered for assessment of concordance with our custom panel since variants near the amplicon boundaries can cause misalignments of multiple reads leading to false-positive or false-negative variant calls (Vijaya Satya et al., 2014) . SnpSift Concordance was used to measure genotype concordance.
Integrative Genomics Viewer (Thorvaldsdóttir et al., 2013) was used to manually inspect some variant calls.
Results and Discussion
Target Enrichment Efficiency
Target capture was inferred from sequence reads, derived from target enrichment amplicons, that mapped to target genes. We defined coverage breadth as the proportion of unique reads that were unambiguously mapped to target regions, and determined coverage breadth per gene and per sample at coverage depth thresholds of 1x, 30x, 50x, and 100x. By examining breadth of coverage per gene and per sample we assessed the sensitivity of capture for each target gene, and uniformity of total target enrichment across samples. In Figure 2 , we show that more than 90% of target sequence for each gene is captured at 30x or greater. The majority of exons are captured at reasonable depth for germline variant calling. We assessed the effect of GC content on coverage depth of amplicons. The Wafergen panel is capable of enriching high GC (> 70%) and low GC (< 30%) regions, but peak coverage depth lies between these extremes of GC as expected from Illumina sequencing (Figure 4 ). Coverage depth tends to increase with GC content. This is driven by the sharp increase in coverage depth from low GC (30% -40%) amplicons to moderate GC (45% -65%) amplicons, and does not represent overall increase in coverage depth across the entire spectrum (26% -81%) of GC content of amplicons. 
Off-target enrichment
We define off-target enrichment as the percentage of reads mapping to other regions of the genome outside the capture target per sample. We observed that off-target enrichment ranges between 7.2% and 22.3%, with mean of 17.3% and standard deviation 3.7%.
Concordance in genotype calls
Using sanger sequencing, 10 germline heterozygous, pathogenic mutations were identified for 10 WaferGen samples. These mutations were confirmed in the relevant samples with the same zygosity identified by Sanger sequencing (Table 3) . Table 3 . Contigency table of genotype counts for 41 variant loci across 19 matching samples representing the relationship between genotype calls for WaferGen and Qiagen panels. 0/0 is homozygous reference, 0/1 is heterozygous, and 1/1 denotes homozygous alternate.
Gene
Conclusions
We demonstrated that our custom hereditary breast cancer panel adequately captures all exons of 13 breast cancer susceptibility genes for next generation sequencing and subsequent detection of germline mutations associated with breast cancer. The WaferGen panel is sensitive for target genes with minimal off-target amplification. At least 90% of target region is captured at reasonable depth (at least 30x) for reliable variant calling, with uniform capture across samples. Additionally, our custom panel can confirm known pathogenic mutations, including SNPs and short deletions, and is comparable to more established Qiagen human breast cancer panel in terms of amplifying exome targets for high confidence variant calling.
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